Will Weakness in SonoScape Medical Corp.'s (SZSE:300633) Stock Prove Temporary Given Strong Fundamentals?
Will Weakness in SonoScape Medical Corp.'s (SZSE:300633) Stock Prove Temporary Given Strong Fundamentals?
With its stock down 4.5% over the past month, it is easy to disregard SonoScape Medical (SZSE:300633). However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive long-term market outcomes, the company is worth looking at. In this article, we decided to focus on SonoScape Medical's ROE.
过去一个月里,索诺斯凯普医疗公司的股价下跌了4.5%,人们很容易忽视它。然而,仔细看看它稳健的财务状况可能会让你重新考虑。鉴于基本面因素通常会推动长期市场结果,该公司值得关注。在本文中,我们决定重点关注SonoScape Medical的净资产收益率(ROE)。
Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.
股本回报率(ROE)是用来评估公司管理层利用公司资本效率的关键指标。简而言之,净资产收益率显示了每一美元相对于其股东投资产生的利润。
See our latest analysis for SonoScape Medical
查看我们对SonoScape Medical的最新分析
How Is ROE Calculated?
净资产收益率是如何计算的?
The formula for ROE is:
这个净资产收益率公式是:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回报率=(持续经营的)净利润?股东权益
So, based on the above formula, the ROE for SonoScape Medical is:
因此,根据上述公式,SonoScape Medical的净资产收益率为:
15% = CN¥445m ÷ CN¥3.1b (Based on the trailing twelve months to September 2023).
15%=4.45亿元×31亿元(以截至2023年9月的12个月为基础)。
The 'return' refers to a company's earnings over the last year. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.15 in profit.
“回报”指的是一家公司过去一年的收益。这意味着,每增加价值1元的股东权益,公司就会产生0.15元的利润。
Why Is ROE Important For Earnings Growth?
为什么净资产收益率对收益增长很重要?
So far, we've learned that ROE is a measure of a company's profitability. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.
到目前为止,我们了解到净资产收益率是衡量一家公司盈利能力的指标。根据公司将这些利润再投资或“保留”多少,以及这样做的效率如何,我们就能够评估一家公司的收益增长潜力。假设其他条件相同,与没有相同特征的公司相比,拥有更高股本回报率和更高利润保留率的公司通常会有更高的增长率。
A Side By Side comparison of SonoScape Medical's Earnings Growth And 15% ROE
索诺斯凯普医疗公司盈利增长与15%净资产收益率的并列比较
To begin with, SonoScape Medical seems to have a respectable ROE. Further, the company's ROE compares quite favorably to the industry average of 10%. This probably laid the ground for SonoScape Medical's significant 26% net income growth seen over the past five years. We believe that there might also be other aspects that are positively influencing the company's earnings growth. Such as - high earnings retention or an efficient management in place.
首先,索诺斯凯普医疗公司似乎拥有令人尊敬的净资产收益率。此外,该公司的净资产收益率(ROE)与行业平均水平10%相比相当有利。这可能为SonoScape Medical在过去五年中实现26%的净利润大幅增长奠定了基础。我们认为,可能还有其他方面正在积极影响公司的收益增长。例如-高收益留存或有效的管理到位。
We then compared SonoScape Medical's net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 17% in the same 5-year period.
然后,我们将SonoScape Medical的净收入增长与行业进行了比较,我们很高兴地看到,与行业相比,该公司的增长数字更高,后者在同一5年期间的增长率为17%。
![past-earnings-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231028/0-66e899808d2f4114630c873612ec5fcc-0-a3cae4afe54ebcf74418e25bd0d5920e.png/big)
Earnings growth is a huge factor in stock valuation. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. Is 300633 fairly valued? This infographic on the company's intrinsic value has everything you need to know.
盈利增长是股票估值的一个重要因素。投资者应该尝试确定预期的收益增长或下降是否已计入价格,无论是哪种情况。这有助于他们确定这只股票是为光明还是黯淡的未来做准备。300633的价值公平吗?这张关于公司内在价值的信息图包含了你需要知道的一切。
Is SonoScape Medical Using Its Retained Earnings Effectively?
SonoScape Medical是否有效地利用了其留存收益?
SonoScape Medical's three-year median payout ratio to shareholders is 17%, which is quite low. This implies that the company is retaining 83% of its profits. So it seems like the management is reinvesting profits heavily to grow its business and this reflects in its earnings growth number.
SonoScape Medical对股东的三年派息率中值为17%,相当低。这意味着该公司将保留83%的利润。因此,管理层似乎正在对利润进行大量再投资,以增长业务,这反映在其收益增长数字上。
Additionally, SonoScape Medical has paid dividends over a period of six years which means that the company is pretty serious about sharing its profits with shareholders. Based on the latest analysts' estimates, we found that the company's future payout ratio over the next three years is expected to hold steady at 15%. However, SonoScape Medical's ROE is predicted to rise to 18% despite there being no anticipated change in its payout ratio.
此外,SonoScape Medical在六年的时间里支付了股息,这意味着该公司非常认真地与股东分享利润。根据最新的分析师预估,我们发现该公司未来三年的派息比率预计将稳定在15%。然而,尽管派息率没有预期的变化,但SonoScape Medical的净资产收益率预计将上升至18%。
Conclusion
结论
Overall, we are quite pleased with SonoScape Medical's performance. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. The latest industry analyst forecasts show that the company is expected to maintain its current growth rate. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.
总体而言,我们对SonoScape Medical的表现相当满意。特别是,我们喜欢该公司对其业务进行大量再投资,并以高回报率进行投资。不出所料,这导致了令人印象深刻的收益增长。最新的行业分析师预测显示,该公司有望保持目前的增长速度。要了解更多分析师对该公司的最新预测,请查看分析师对该公司预测的可视化。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。